PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR

摘要

The present invention relates to a pharmaceutical composition comprising
a) a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof,b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties;c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties;d) one or more, e.g. 1, 2 or 3, fillers, ande) one or more, e.g. 1, 2 or 3, disintegrants.

主权项

1. A pharmaceutical composition in the form of a tablet comprising
a) a therapeutically effective amount of the sodium salt of the compound trans-(4-{4-[5-(6-trifluromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid b) 0.1 to 5% of sodium lauryl sulfate by weight of the tablet prior to any optional film coating; c) 2 to 20% of hydroxypropyl cellulose by weight of the tablet prior to any optional film coating; d) 15-50% of microcrystalline cellulose by weight of the tablet prior to any optional film coating; e) 0.1-1.0% of colloidal silica by weight of the tablet prior to any optional film coating; f) 0.1-10% of sodium stearyl fumarate by weight of the table prior to any optional film coating; g) 4 to 85% of anhydrous lactose by weight of the tablet prior to any optional film coating of; h) 0.5 to 10% of sodium starch glycolate by weight of the tablet prior to any optional film coating; and i) an optional film coating.